AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Health Information Services

$ACON

Aclarion, Inc.

Price · $ACONvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ACON in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $ACON in the last 30 days.

See all $ACON insider activity →
Top stories · $ACONMore →
OCT 8·rttnews.comMed

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

ACON sentiment & insider activity

Recent ACON coverage spans insider activity, financial news and technology.

What's driving ACON

  • The enrollment change is expected to increase patient flow and may improve trial timelines, supporting the stock.

    rttnews.com · Oct 8, 2026

  • Small insider buy may signal confidence but limited market impact due to modest size.

    SEC EDGAR · Aug 19, 2026

  • This is an insider open-market buy by the CFO, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 18, 2026

  • This is a director open-market buy disclosed via Form 4, which can be mildly supportive for sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 17, 2026

  • The filing discloses a director adding shares via an open-market purchase, but the disclosed size is small and lacks guidance or operational catalysts.

    SEC EDGAR · Aug 17, 2026

AlphAI scores every news story that mentions ACON with an AI model for sentiment and relevance, and aggregates insider trades from Aclarion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACON

Score
OCT 8$ACONMedAI 8/10rttnews.com

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

2 min read
AUG 12$ACONLowfinanznachrichten.de

Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.

3 min read

Related tickers

More in Health Information Services